How did AMVUTTRA™ help patients?

In an 18-month clinical study, AMVUTTRA-treated patients showed significant improvement in nerve function and quality of life at 9 months and continued to improve throughout the study, compared with those who received placebo in a similar study.

Choose below to see:

At 9 months, AMVUTTRA significantly improved nerve function while patients who received placebo got worse.

At 18 months, 48% of patients who received AMVUTTRA regained some nerve function from the start of treatment, compared with 4% of those who received placebo.

  • For the patients who received AMVUTTRA and did not regain some nerve function, progression of their neuropathy was slowed compared with those who received placebo

Nerve function was assessed using a scale called mNIS+7 that measured strength and sensation in the hands, feet, arms, and legs; reflexes; and blood pressure upon standing.

At 9 months, AMVUTTRA significantly improved quality of life while patients who received placebo got worse.

At 18 months, 57% of patients who received AMVUTTRA reported better quality of life from the start of treatment, compared with 10% of those who received placebo.

Quality of life was evaluated by the Norfolk QoL-DN questionnaire that asked patients about the severity of their polyneuropathy symptoms, how often they experienced them, and what impact they felt they had on their daily lives.

Choose below to see:

Amvuttra treatment vs Placebo treatment

At 9 months, AMVUTTRA significantly improved nerve function while patients who received placebo continued to get worse.

Nerve function icon

At 18 months, 48% of patients who received AMVUTTRA regained some nerve function from their starting point in the study, compared with 4% of those who received placebo.

  • For the patients who received AMVUTTRA and did not regain some nerve function, progression of their neuropathy was slowed compared with those who received placebo

Nerve function was assessed using a scale called mNIS+7 that measured strength and sensation in the hands, feet, arms, and legs; reflexes; and blood pressure upon standing.

Amvuttra treatment vs Placebo treatment

At 9 months, AMVUTTRA significantly improved quality of life while patients who received placebo continued to get worse.

Quality of life

At 18 months, 57% of patients who received AMVUTTRA reported better quality of life from their starting point in the study, compared with 10% of those who received placebo.

Quality of life was evaluated by the Norfolk QoL-DN questionnaire that asked patients about the severity of their polyneuropathy symptoms, how often they experienced them, and what impact they felt they had on their daily lives.

Ask your doctor, “Is AMVUTTRA right for me?”

What other improvements did patients experience?

The effects of AMVUTTRA on other aspects of the disease, including walking ability, nutritional health, and ability to perform activities of daily living, were also evaluated at 18 months and compared with the effects of placebo in a similar study.

Walking ability
Toggle item
Gait speed icon

AMVUTTRA-treated patients maintained a better walking speed, compared with patients who received placebo

  • Evaluated using the 10-meter walk test, a stopwatch-timed measure of a patient’s walking speed over 10 meters 
Nutritional health
Toggle item
Nutrition icon

AMVUTTRA-treated patients experienced improvement in nutritional health, compared with patients who received placebo

  • Evaluated using modified body mass index, an assessment of height, weight, and the balance of fluids in the body
  • In patients with the polyneuropathy caused by the disease, gastrointestinal distress can lead to a decline in nutritional health
Activities of daily living
Toggle item
Everday activities

AMVUTTRA-treated patients were better able to perform common daily activities, compared with patients who received placebo

  • Assessed using a 24-item questionnaire called R-ODS, in which patients rated their ability to complete tasks at the beginning of the study and at the end of the study
  • Common daily activities included showering, brushing teeth, dressing upper body, going shopping, doing dishes, and walking up a flight of stairs

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about AMVUTTRA™ (vutrisiran)?

AMVUTTRA can cause:

  • Low Vitamin A Levels

    Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

    Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Important Safety Information and Indication

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about AMVUTTRA™ (vutrisiran)?

AMVUTTRA can cause:

  • Low Vitamin A Levels

    Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

    Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about AMVUTTRA™ (vutrisiran)?

AMVUTTRA can cause:

  • Low Vitamin A Levels

    Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

    Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Alnylam logo

AMVUTTRA, Alnylam Assist, and their associated logos are trademarks of Alnylam Pharmaceuticals, Inc.

© 2022 Alnylam Pharmaceuticals, Inc. All rights reserved. This site is intended for US audiences.    AMV-USA-00055